Association of medullary carcinoma of the thyroid with carcinoembryonic antigen

Ishikawa, Naoki; Hamada, Shin

doi:10.1038/bjc.1976.133

Cited by 113 publications

(37 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quite recently we have demonstrated that carcinoembryonic antigen (CEA), a tumor-associated fetal antigen described by Gold and Freedman (1965), is markedly increased in sera and tissues of the MCT in contrast with other types of thyroid carcinomas (Ishikawa and Hamada, 1976). The results obtained prompted us to investigate the relationship between CEA levels and cellular activity of the tumor, making comparison with the CT secretion.…”

Section: Synopsismentioning

confidence: 95%

See 1 more Smart Citation

Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: A comparative study.

et al. 1976

View full text Add to dashboard Cite

SynopsisCarcinoembryonic antigen (CEA) and calcitonin (CT) were simultaneously determined in sera and tumor tissues from 15 patients with medullary carcinoma of the thyroid (MCT). Serum CEA was increased in all but one patient, and CT did in all of them. Both levels were significantly related to the weight of excised tumor, but not to the presence of metastasis.Furthermore, a significant correlation was noted between the basal levels of CT and CEA. Both levels fell to normal after a radical operation had been performed.Tissue concentrations of CEA and CT in the MCT were more than 100 times those in hyperthyroidism, and the ratios of tissue over serum levels averaged 770 in CEA and 1000 in CT. In the calcium infusion test, CEA levels were not significantly changed in contrast with a distinct increase in CT levels. The results indicate that CEA and CT represent separate activities of the tumor cells, and that circulating CEA together with CT is a useful indicator in the diagnosis and follow-up of the disease.

show abstract

Section: Synopsismentioning

confidence: 95%

“…Positive CEA find-ings were also very high, though slightly lower compared with CT, and further, the levels in excess of 40ng/ml ("diagnostic levels") were shown in 86.7%. Because elevated levels of CEA are rarely seen in other thyroid diseases (Ishikawa and Hamada, 1976), CEA assay appears very useful for diagnosis of the MCT.…”

Section: Synopsismentioning

confidence: 99%

Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: A comparative study.

et al. 1976

View full text Add to dashboard Cite

show abstract

“…Because an MTC tumor expresses and secretes carcinoembryonic antigen (CEA), it constitutes a potential application for radioimmunotherapy with anti-CEA antibodies (13). Our group demonstrated the efficacy of radioimmunotherapy in the treatment of MTC in animal model or in phase I/ II clinical trials (14)(15)(16)(17).…”

mentioning

confidence: 98%

Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen–Expressing Medullary Thyroid Cancer Xenograft

Kraeber-Bodéré¹,

Bodet-Milin²,

Niaudet³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

A significant antitumor effect was previously observed with radioimmunotherapy using anti-carcinoembryonic antigen 131 I-F6 monoclonal antibody in medullary thyroid cancer-bearing nude mice. Nevertheless, no complete response was observed. As seen with chemotherapy, drugs targeting the tumor microenvironment might improve radioimmunotherapy efficacy. This study evaluated the toxicity and efficacy of combining radioimmunotherapy with thalidomide or a cyclopeptidic vascular endothelial growth inhibitor (CBOP11) in mice grafted with the TT human medullary thyroid cancer cell line. Methods: Six to 10 nude mice treated with 92.5 MBq of 131 I-F6 in association with 200 mg/kg/d of oral thalidomide during 20 d by force-feeding or 0.45 mg/kg/d of CBOP11 during 25 d using subcutaneous minipumps were compared with control mice receiving either treatment or naked F6 or nonspecific 131 I-734. Combined therapies included 131 I-F6 at day 0 followed by thalidomide between days 20 and 40, thalidomide between days 0 and 20 followed by 131 I-F6 at day 25, 131 I-F6 at day 0 and CBOP11 between days 0 and 25, CBOP11 between days 0 and 25 followed by 131 I-F6 at day 25, and 131 I-F6 at day 0 followed by CBOP11 between days 20 and 45. Animal weight, hematologic toxicity, tumor volume, and serum calcitonin were monitored for the following 3 mo. Improvement of 125 I-F6 tumor biodistribution by antiangiogenic drug was studied after pretreatment by thalidomide. Follow-up of the tumor after combined antiangiogenic and radioimmunotherapy therapies was performed by histology studies. Results: Combined associations, as compared with radioimmunotherapy alone, increased leukopenia but not thrombocytopenia. Tumor volume-quadrupling time (TVQT) was 22.8 6 3.3 d in the control group, 29.9 6 3.6 d in the group treated with thalidomide, 34.6 6 4.4 d in the group treated with CBOP11, and 51.0 6 2.8 d after radioimmunotherapy alone. As compared with radioimmunotherapy, TVQT was significantly longer (P , 0.01) after thalidomide followed by radioimmunotherapy (69.83 6 3.9), CBOP11 followed by radioimmunotherapy (71.3 6 6.1), and CBOP11-radioimmunotherapy in concomitance (64.2 6 6.1). Nevertheless, TVQT was not increased after radioimmunotherapy followed by thalidomide (48.8 6 4) and radioimmunotherapy followed by CBOP11 (56.8 6 4.8). Surprisingly, pretreatment by CBOP11 or thalidomide sensitized larger tumors (.300 mm 3 ) to radioimmunotherapy. Change in calcitonin levels confirmed morphologic tumor response. Tumor uptake 24 h after injection of 125 I-F6 was 4.5 6 0.6 percentage injected dose per gram (%ID/g) without pretreatment and 8.7 6 1.3 %ID/g with pretreatment by thalidomide. An increase of the antitumor effect observed using the antiangiogenic drug combined with radioimmunotherapy was correlated with a decrease of blood vessels shown by von Willebrand immunostaining. Conclusion: Pretreatment with antiangiogenic therapies improved radioimmunotherapy efficacy, with acceptable toxicity. Future investigations will be performed to understand how antia...

show abstract

“…Because MTC expresses and secretes carcinoembryonic antigen (CEA), it constitutes a potential application for RIT with anti-CEA antibodies. 13 Our group demonstrated the efficacy of RIT in the treatment of MTC in animal models and in phase 1 and 2 clinical trials. [14][15][16][17] Nevertheless, RIT efficacy must be improved, in particular, in cases of aggressive forms or large tumor masses.…”

mentioning

confidence: 99%

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma

Salaun

Bodet-Milin

Frampas

et al. 2010

Cancer

View full text Add to dashboard Cite

2,3‐Diaryl substituted maleimides as model compounds of conjugated maleimide polymers [poly(RMI‐alt‐Ar) and poly(RMI‐co‐Ar)] were synthesized from 2,3‐dibromo‐N‐substituted maleimide (DBrRMI) [R= cyclohexyl (DBrCHMI) and n‐hexyl (DBrHMI)] and aryl boronic acid using palladium catalysts. To clarify structures of conjugated polymer containing maleimide units at the main chain, 13C NMR spectra of 2‐aryl or 2,3‐diaryl substituted maleimides were compared with those of N‐substituted maleimide polymers. Copolymers obtained with DBrRMI via Suzuki‐Miyaura cross‐coupling polymerizations or Yamamoto coupling polymerizations were dehalogenated structures at the terminal end. This dehalogenation may contribute to the low polymerizability of DBrRMIs. On the other hand, the π‐conjugated compounds showed high solubility in common organic solvents. The N‐substituents of maleimide cannot significantly affect the photoluminescence spectra of 2,3‐diaryl substituted maleimides derivatives. The fluorescence spectra of poly(RMI‐alt‐Ar) and poly(RMI‐co‐Ar) varied with N‐substituents of the maleimide ring. When exposed to ultraviolet light of wavelength 352 nm, a series of 1,4‐phenylene‐ and/or 2,5‐thienylene‐based copolymers containing N‐substituted maleimide derivatives fluoresced in a yellow to blue color. It was found that photoluminescence emissions and electronic state of π‐conjugated maleimide derivatives were controlled by aryl‐ and N‐substituents, and maleimide sequences of copolymers. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

show abstract

Association of medullary carcinoma of the thyroid with carcinoembryonic antigen

Cited by 113 publications

References 10 publications

Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: A comparative study.

Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: A comparative study.

Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen–Expressing Medullary Thyroid Cancer Xenograft

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma

Contact Info

Product

Resources

About